2022 is starting on a worrisome note; patience warranted
13/01/22 -"While the fundamental metrics (i.e. DCF and NAV) continue to point to healthy upside potential (taking into consideration the long-term virtues of Philips’ offerings), the near-term is fraught with ..."
Pages
63
Language
English
Published on
13/01/22
You may also be interested by these reports :
13/05/24
DiaSorin started 2024 on a promising note with sales and profitability exceeding expectations. Healthy growth across segments was offset by waning ...
10/05/24
While the 2023 EPS benefitted from material deferred tax income, we have moderated our earnings estimates for 2024-25 owing to high interest rates ...
10/05/24
Fresenius reported Q1 figures that exceeded the consensus, with revenues increasing by 0.3%, adjusted EBIT by 4.5%, net income from continuing ...
09/05/24
Smith & Nephew reported marginally softer than expected Q1 24 numbers. The weakness was largely attributable to US implants and areas within wound ...